What Is Genomics?
Genomic testing looks at the DNA of your cancer to find mutations. These changes may help your doctor choose more targeted and effective treatments.
One key gene is KRAS. It helps control how cells grow.
More than 90% of pancreatic adenocarcinomas have a KRAS mutation. Different mutations can affect how the cancer grows and responds to treatment. The most common are:
-G12D – ~40%
- G12V – ~33%
G12R – ~17% (new treatments in development)
G12C – ~2% (some treatments available)
*KRAS pathways. All the common mutations G12D, G12V, G12C, and G12S operate through PI3K alpha, and have no effector protein to interact with the MEK inhibitors. In contrast, G12R operates through PI3K gamma and HAS an effector protein that interacts with MEK inhibitor. This interaction is augmented in the presenceof gemcitabine/ gemzar (chemotherapy drug).
If You Have the G12R Mutation We’re Here to Help
The G12R mutation is found in about 17% of pancreatic adenocarcinomas. If you have this mutation, there’s promising news.
Our team discovered that adding a MEK inhibitor to standard chemotherapy can significantly improve survival.
Drugs like trametinib and cobimetinib may become part of your treatment plan.
Early research shows that patients with G12R may have the best survival outcomes among all KRAS codon 12 mutations.
We’re committed to advancing care for G12R — and supporting you every step of the way.